Dare Bioscience (DARE) director receives 10,000 stock option grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Dare Bioscience director William H. Rastetter received a grant of stock options for 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036. They vest in full on the earlier of the first anniversary of the grant date or immediately before the company’s first annual shareholder meeting after the grant date, subject to his continued board service. The options also become fully exercisable upon a change in control of Dare Bioscience.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider RASTETTER WILLIAM H

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	10,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 10,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Stock options granted: 10,000 options Exercise price: $2.03 per share Expiration date: June 11, 2036 +1 more

4 metrics

Stock options granted 10,000 options Grant to director on June 11, 2026

Exercise price $2.03 per share Stock option exercise price

Expiration date June 11, 2036 Option term end

Total options following transaction 10,000 options Director’s derivative holdings after grant

Key Terms

Stock Option (right to buy), exercise price, change in control, vest in full

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price": "2.0300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

change in control financial

"will become exercisable in full upon a change in control of the issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

vest in full financial

"This option will vest in full on the earlier of the first anniversary"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/11/2026 - 05:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RASTETTER WILLIAM H

(Last)

(First)

(Middle)

3655 NOBEL DRIVE

SUITE 260

(Street)

SAN DIEGO

CALIFORNIA

92122

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dare Bioscience, Inc. [ DARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$2.03	06/11/2026		A		10,000		⁽¹⁾	06/11/2036	Common stock	10,000	$0	10,000	D

Explanation of Responses:

1. This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer.

Remarks:

	/s/ Sabrina Martucci Johnson, Attorney-in-fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Dare Bioscience (DARE) disclose in this Form 4 for William H. Rastetter?

Dare Bioscience reported that director William H. Rastetter received a grant of stock options for 10,000 shares of common stock. The options were awarded as a compensation-related grant and are not an open-market purchase or sale of existing shares.

What are the key terms of William H. Rastetter’s 10,000 Dare Bioscience stock options?

The grant covers 10,000 stock options with an exercise price of $2.03 per share and an expiration date of June 11, 2036. These options give him the right, but not the obligation, to buy Dare Bioscience common shares at that fixed price.

How do William H. Rastetter’s Dare Bioscience options vest according to the Form 4?

The options will vest in full on the earlier of the first anniversary of the June 11, 2026 grant date or immediately before Dare Bioscience’s first annual shareholder meeting after that date. Vesting requires his continued service as a director until that vesting event.

What happens to William H. Rastetter’s options if Dare Bioscience experiences a change in control?

The Form 4 footnote states the options will become fully exercisable upon a change in control of Dare Bioscience. This means that if such a transaction occurs, all 10,000 options would immediately be exercisable regardless of the normal vesting schedule.

Did William H. Rastetter buy or sell Dare Bioscience common stock in this filing?

No open-market buys or sells of Dare Bioscience common stock were reported. The filing shows only a grant of derivative securities: 10,000 stock options, classified as an acquisition under code A, with no corresponding sale transactions disclosed.

How many Dare Bioscience derivative securities does William H. Rastetter hold after this transaction?

After the grant, William H. Rastetter is reported as holding 10,000 stock options directly. These options are exercisable into 10,000 shares of Dare Bioscience common stock, reflecting his entire derivative position shown in this particular Form 4.